Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$138.78

-0.89 (-0.64%)

, SNY

Sanofi

$47.44

-0.76 (-1.58%)

11:06
06/12/17
06/12
11:06
06/12/17
11:06

Tesaro rallies after web report claims Sanofi interested in buyout

Sanofi (SNY) and at least one other suitor have expressed interest in acquiring Tesaro (TSRO), website Street Insider reports, citing "a person claiming to have knowledge of the matter." The second company is likely Gilead Sciences (GILD), and a deal could be worth $10B, the website speculated. Shares of Tesaro, a frequent subject of takeout conjecture, have rallied off the day's lows and are now up $1.22 to $140.00. The company's market capitalization is around $7.40B.

TSRO

Tesaro

$138.78

-0.89 (-0.64%)

SNY

Sanofi

$47.44

-0.76 (-1.58%)

GILD

Gilead

$64.70

0.58 (0.90%)

  • 13

    Jun

  • 13

    Jun

  • 30

    Jun

TSRO Tesaro
$138.78

-0.89 (-0.64%)

06/12/17
RHCO
06/12/17
NO CHANGE
RHCO
Misunderstanding creates buying opportunity in Tesaro stock, says SunTrust
SunTrust analyst Peter Lawson says that the suspension of participant recruitment by Johnson & Johnson (JNJ) for a study of Tesaro's (TSRO) PARP inhibitor Zejula in prostate cancer "is being incorrectly viewed as a clinical hold." After speaking with J&J, Lawson says that the suspension was not due to clinical or safety issues, but to overly fast enrollment. The analyst says that the early data on PARP inhibitors in prostate cancer has been "encouraging." He believes that the misunderstanding has created a buying opportunity in Tesaro stock. .
06/09/17
FBCO
06/09/17
NO CHANGE
FBCO
Outperform
Tesaro prostate study suspension due to fast enrollment, says Credit Suisse
After speaking to Tesaro (TSRO), after they spoke to their partner Johnson & Johnson (JNJ), Credit Suisse analyst Alethia Young said the news of the companies' suspension of participant recruitment in the study of niraparib in prostate cancer is actually positive, since it is due to the trial enrolling faster than expected. The suspension has nothing to do with safety or efficacy and is not a clinical hold, but is due to having too many patients in the first part of trial, Young was told. She maintains an Outperform rating on Tesaro shares.
06/09/17
06/09/17
NO CHANGE

Tesaro tells Janney 'no clinical hold, no suspension' in prostate cancer study
After Tesaro (TSRO) shares saw weakness earlier associated with a notice indicating that enrollment was halted in its Johnson & Johnson (JNJ) partnered prostate cancer study, the company told Janney Capital analyst Debjit Chattopadhyay that there is "no clinical hold, no suspension, no safety issues, nothing going on. The first cohort enrolled quickly and we need to see data before starting to enroll the next group - standard trial conduct... JNJ's screening pool was large due to interest, and screen failure rate was lower than expected. Hence, JNJ stopped screening or they would be at risk of enrolling the whole trial before they get to the first data from run in." The analyst, who expect Tesaro shares to be range bound until peer data and regulatory events, keeps a Neutral rating on the stock, which has recovered all of its earlier losses and is now about flat for the session.
06/09/17
WELS
06/09/17
NO CHANGE
WELS
Tesaro trial suspension 'normal' conduct, says Wells Fargo
Wells Fargo analyst Jim Birchenough says the trial recruitment suspension posted on ClinicalTrials.gov is "normal trial conduct" and does not represent any issues. Tesaro shares, after initially selling off on the news, is unchanged on the day.
SNY Sanofi
$47.44

-0.76 (-1.58%)

06/12/17
LEER
06/12/17
NO CHANGE
Target $493
LEER
Outperform
Regeneron's Dupixent tracking well above consensus, says Leerink
Leerink analyst Geoffrey Porges says prescription trends suggest Regeneron (REGN) and Sanofi's (SNY) Dupixent will "comfortably exceed" current sell-side consensus expectations for this quarter and year. After 10 weeks, the prescription launch trajectory "remains very robust," Porges tells investors in a research note. The analyst views his Q2 sales estimate of $31M, versus the $16M consensus, as "reasonable," and feels full year sales of $200M-300M, versus the consensus of $135-$140M, is likely. He reiterates an Outperform rating on Regeneron shares.
06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
05/11/17
BREN
05/11/17
DOWNGRADE
BREN
Hold
Sanofi downgraded to Hold from Buy at Berenberg
Berenberg analyst Alister Campbell downgraded Sanofi to Hold citing valuation.
04/11/17
04/11/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Conviction Buy from Buy at Goldman with analyst Drew Borst saying that the success of "Beauty and the Beast" has increased his confidence in his forecast that FY18 EPS growth will accelerate given the company's promising film slate and its read-through to consumer products. He also sees accelerating profit growth at ESPN given normalizing NBA costs and predicts record results for the Theme Parks segment. Borst keeps a $138 price target on Disney shares. 2. McDonald's (MCD) upgraded to Buy from Neutral at Cleveland Research. 3. Yelp (YELP) upgraded to Overweight from Sector Weight at Pacific Crest with analyst Brad Erickson saying his checks with local ad customers indicate Yelp's core franchise is healthy and appears insulated from larger competitors like Google (GOOG, GOOGL) and Facebook (FB). 4. Toll Brothers (TOL) upgraded to Outperform from Sector Perform at RBC Capital with analyst Robert Wetenhall citing "solid demand,strong execution, proven management, a strong luxury housing business, and consistent earnings." 5. Sanofi (SNY) upgraded to Neutral from Underweight at JPMorgan with analyst Richard Vosser saying he no longer sees downside to consensus estimates. The pressure on the diabetes business now seems largely reflected in estimates, Vosser tells investors in a research note. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GILD Gilead
$64.70

0.58 (0.90%)

05/30/17
JPMS
05/30/17
NO CHANGE
JPMS
Overweight
JPMorgan 'generally encouraged' by Gilead bictegravir data
After Gilead (GILD) announced top-line data from four Phase 3 studies of its HIV combo regimen containing bictegravir, JPMorgan analyst Cory Kasimov said he was "generally encouraged by the news, though not entirely surprised" given the previously communicated Phase 2 results. As he has previously noted, Kasimov thinks the launch of the bictegravir combo in 2018 could be key for Gilead to help maintain market share in the face of continued growth of GlaxoSmithKline's (GSK) dolutegravir combo and a wave of patent expirations. The analyst keeps an Overweight rating on Gilead shares.
05/30/17
LEER
05/30/17
NO CHANGE
Target $74
LEER
Market Perform
Gilead HIV combo data should reassure investors, says Leerink
Leerink analyst Geoffrey Porges said Gilead's (GILD) Phase 3 data for its HIV combination treatment featuring bictegravir should "provide significant reassurance for investors" given that the drug is an essential part of the company's HIV strategy and portfolio and was found to be equal to, though not better than, the "gold standard," namely GlaxoSmithKline's (GSK) dolutegravir combo. Porges, who attributes $12-13 per share in value from bictegravir in his current model for Gilead, notes that his peak global forecast of $10.6B for bictegravir containing combination revenue is nearly double the current consensus peak sales estimate of $5.6B. Porges keeps a Market Preform rating and $74 price target on Gilead shares.
04/25/17
JMPS
04/25/17
NO CHANGE
JMPS
Johsnson &Johnson data positive for Achillion, says JMP Securities
JMP Securities analyst Liisa Bayko says that data on a triple combination HCV treatment presented by Johnson & Johnson (JNJ) yesterday is positive for Achillion (ACHN). The analyst noted that the triple combination includes Achillion's odalasvir and that the six week treatment regimen is shorter than the eight weeks required for Gilead's (GILD) Harvoni. The analyst says that Achillion's stock dropped sharply yesterday because there was disappointment over the combination's efficacy in genotype 3 patients. However, she says that such patients only represent 10% of the total, and she says that Achillion can "conservatively" obtain peak royalty revenue of about $100M from its drug. Bayko keeps a $13 price target and an Outperform rating on the shares.
04/25/17
WELS
04/25/17
NO CHANGE
WELS
Gilead Q1 results poised to beat expectations, says Wells Fargo
After analyzing prescription data for January and February, Wells Fargo says that prescriptions of Gilead's HIV and HCV drugs were tracking ahead of expectations. The firm says the company's Q1 results appear on track to beat expectations.

TODAY'S FREE FLY STORIES

TSLA

Tesla

$312.60

-5.21 (-1.64%)

09:52
11/24/17
11/24
09:52
11/24/17
09:52
Hot Stocks
Tesla lists base price of 300 mile range Semi at $150,000 »

Tesla on its website…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

OSTK

Overstock.com

$61.05

0.6 (0.99%)

09:51
11/24/17
11/24
09:51
11/24/17
09:51
Technical Analysis
Technical View: Overstock.com spikes sharply to new 52-week high »

The stock briefly hit a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$98.68

0.04 (0.04%)

, CME

CME Group

$141.87

-0.71 (-0.50%)

09:50
11/24/17
11/24
09:50
11/24/17
09:50
Hot Stocks
The Intersection: Crypto and Wall Street This Week »

As bitcoin, ethereum and…

JPM

JPMorgan

$98.68

0.04 (0.04%)

CME

CME Group

$141.87

-0.71 (-0.50%)

MS

Morgan Stanley

$49.23

0.14 (0.29%)

MCD

McDonald's

$169.23

0.1804 (0.11%)

AMD

AMD

$11.37

-0.03 (-0.26%)

NVDA

Nvidia

$214.93

-1.12 (-0.52%)

GBTC

Bitcoin Investment Trust

$995.00

23.8 (2.45%)

BITCOIN

Bitcoin

BTC

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 09

    Jan

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

09:42
11/24/17
11/24
09:42
11/24/17
09:42
General news
S&P 500 rises to all time high at start of holiday-shortened session »

Investors returning from…

STAG

STAG Industrial

09:41
11/24/17
11/24
09:41
11/24/17
09:41
Conference/Events
STAG Industrial management to meet with Evercore ISI »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 14

    Dec

ETE

Energy Transfer Equity

, QCOM

Qualcomm

$68.13

1.46 (2.19%)

09:40
11/24/17
11/24
09:40
11/24/17
09:40
Options
Unusually active option classes on open November 24th »

Unusual total active…

ETE

Energy Transfer Equity

QCOM

Qualcomm

$68.13

1.46 (2.19%)

TEVA

Teva

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

COP

ConocoPhillips

09:39
11/24/17
11/24
09:39
11/24/17
09:39
Conference/Events
ConocoPhillips management to meet with Evercore ISI »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

QD

Qudian

09:37
11/24/17
11/24
09:37
11/24/17
09:37
Recommendations
Qudian analyst commentary  »

Qudian price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MET

MetLife

09:37
11/24/17
11/24
09:37
11/24/17
09:37
Conference/Events
MetLife management to meet with Evercore ISI »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 15

    Dec

SOLVY

Solvay

09:35
11/24/17
11/24
09:35
11/24/17
09:35
Conference/Events
Solvay management to meet with Evercore ISI »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

SPY

SPDR S&P 500 ETF Trust

, SPX

S&P 500

09:34
11/24/17
11/24
09:34
11/24/17
09:34
Technical Analysis
Technical View: S&P 500 edges new life high, pivot high broken »

The S&P 500 (SPX) was…

SPY

SPDR S&P 500 ETF Trust

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRFS

Grifols

$23.04

-0.13 (-0.56%)

09:33
11/24/17
11/24
09:33
11/24/17
09:33
Downgrade
Grifols rating change  »

Grifols downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMA

Banco Macro

09:32
11/24/17
11/24
09:32
11/24/17
09:32
Downgrade
Banco Macro rating change  »

Banco Macro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSU

Tim Participacoes

09:32
11/24/17
11/24
09:32
11/24/17
09:32
Upgrade
Tim Participacoes rating change  »

Tim Participacoes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:30
11/24/17
11/24
09:30
11/24/17
09:30
General news
PMI Composite Flash â€' Level to be reported at 09:45 »

November PMI Composite…

09:30
11/24/17
11/24
09:30
11/24/17
09:30
General news
PMI Composite Flash Manufacturing â€' Level to be reported at 09:45 »

November PMI Composite…

DSX

Diana Shipping

09:25
11/24/17
11/24
09:25
11/24/17
09:25
Hot Stocks
Diana Shipping announces time charter contract for m/v Norfolk »

Diana Shipping announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LAUR

Laureate Education

$11.63

0.22 (1.93%)

09:25
11/24/17
11/24
09:25
11/24/17
09:25
Recommendations
Laureate Education analyst commentary  »

Laureate received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$41.01

4.31 (11.74%)

09:23
11/24/17
11/24
09:23
11/24/17
09:23
Recommendations
Copart analyst commentary  »

Copart price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

09:18
11/24/17
11/24
09:18
11/24/17
09:18
Options
Overnight activity included 97 trades in SPX and 9 trades in VIX »

97 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRAX

Social Reality

$5.82

1.59 (37.59%)

09:14
11/24/17
11/24
09:14
11/24/17
09:14
Technical Analysis
Technical View: Social Reality trades sharply higher in pre-market »

At time of writing the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXC

Exelon

09:10
11/24/17
11/24
09:10
11/24/17
09:10
Conference/Events
Exelon management to meet with Evercore ISI »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 30

    Nov

  • 01

    Dec

PN

Patriot National

09:10
11/24/17
11/24
09:10
11/24/17
09:10
Hot Stocks
Breaking Hot Stocks news story on Patriot National »

Patriot National trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$13.48

0.15 (1.13%)

, QD

Qudian

$16.15

-3.16 (-16.36%)

09:09
11/24/17
11/24
09:09
11/24/17
09:09
Hot Stocks
On The Fly: Pre-market Movers »

HIGHER: Teva…

TEVA

Teva

$13.48

0.15 (1.13%)

QD

Qudian

$16.15

-3.16 (-16.36%)

RYB

RYB Education

$26.71

-1.1 (-3.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

CLSN

Celsion

$3.13

0.27 (9.44%)

09:06
11/24/17
11/24
09:06
11/24/17
09:06
Technical Analysis
Technical View: Celsion trades sharply higher in pre-market »

At time of writing in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.